TICKERNERD
Menu
AZTRAZTRHealthcare · Biotechnology

AZTR Stock Forecast: Azitra, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.77

The 1 Wall Street analysts covering Azitra, Inc. hold a median 12-month price target of $6.7 — +771.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$4.7M
Ticker Nerd rank
42/ 100
Median analyst target
$6.70
Analysts covering
1
Revenue$0.0
Operating income−$3.4M
Net income−$3.3M
Free cash flow−$3.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

AZTR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Azitra, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Revisions
84
Accruals
70
Growth
39
Issuance
37
Momentum
31
Volatility
29
Quality
14
Value
8

Size (95): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AZTR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AZTR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $3.40Median $6.70High $10.00

The green dot is the last close — the median target sits +771.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Sept 2025Maxim GroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AZTR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

AZTR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Azitra, Inc. (AZTR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
6.6×

Cheaper than 64% of US stocks

Price / sales
—
Price / book
0.6×

Cheaper than 80% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−256.7%

Higher than 6% of US stocks

Return on assets
−119.9%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Azitra, Inc. (AZTR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Azitra, Inc. has a market value of $4.7M and an enterprise value of −$1.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$11.4M, after $212K of capital spending.

  • Shares outstanding: 16.2M.

  • Trailing P/E: 6.6×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Azitra, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

AZTR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AZTRAzitra, Inc.$4.7M42
XBIOXenetic Biosciences, Inc.$4.8M31
TRAWTraws Pharma, Inc.$4.5M48
CDIOCardio Diagnostics Holdings, Inc.$4.9M20
CELZCreative Medical Technology Holdings, Inc.$4.3M21
IMNNImunon, Inc.$5.1M23
PULMPulmatrix, Inc.$5.1M48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Azitra, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AZTR news & analysis

Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors

PRNewsWire · 29 Oct 2026positive

Azitra amended its ongoing Phase 1/2 trial of ATR-04 to include patients with rashes associated with KRAS and MEK inhibitors, in addition to EGFR inhibitor-associated rash. The company said further protocol modifications are expected to facilitate recruitment and accelerate enrollment.

Why it matters — The expanded eligibility broadens the patient groups being considered for ATR-04 and may affect the trial’s enrollment process.

Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin

PRNewsWire · 26 Oct 2026positive

Azitra reported that its ATR-COSF cosmetic candidate showed visible improvements in fine lines, wrinkles, and elasticity in two ex vivo human-skin models after a single dose, with improvement continuing through 48 hours. The company anticipates initial results from a first-in-human study by year end.

Why it matters — The ex vivo findings and anticipated first-in-human results provide updates on ATR-COSF’s development.

Azitra, Inc. Announces Reverse Stock Split

PRNewsWire · 16 Oct 2026neutral

Azitra announced it intends to effect a 1-for-10 reverse stock split of its common stock. The shares are scheduled to begin trading on a split-adjusted basis on October 26, 2026.

Why it matters — AZTR watchers may note the planned change to the number of shares outstanding and the date split-adjusted trading is expected to begin.

Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance

PRNewsWire · 1 Oct 2026positive

Azitra, Inc. announced completion of Cohort 1 in its Phase 1/2 clinical trial evaluating ATR04-484 as a potential treatment for EGFR inhibitor-associated skin rash, and received Safety Review Committee clearance to advance the trial to Cohort 2.

Why it matters — This marks forward clinical progress for Azitra's lead dermatology candidate ATR04-484 after passing a safety review milestone.

Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 8 Sept 2026neutral

Azitra, Inc. announced that Travis Whitfill, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 8, 2026. The clinical-stage biopharmaceutical company focuses on precision dermatology and high value cosmetic proteins and peptides.

Why it matters — The presentation gives Azitra an opportunity to showcase its business and pipeline to the institutional investment community at a major industry conference.

FAQ

Frequently asked questions about AZTR stock

What is the AZTR stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Azitra, Inc. have a median 12-month price target of $6.7, with estimates ranging from $3.4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AZTR stock a buy right now?

Of the 1 analysts covering Azitra, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Azitra, Inc. 42 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AZTR?

As at 31 Oct 2026, Azitra, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will AZTR stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +771.0% from the last close, and Ticker Nerd's factor model ranks Azitra, Inc. 42 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AZTR stock forecast for 2030?

No analyst covering Azitra, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AZTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.4 to $10 over the next 12 months.

What does Azitra, Inc. do?

Azitra Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology.

What is the latest news on AZTR?

The most recent item we track (PRNewsWire, 29 Oct 2026): "Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors". Azitra amended its ongoing Phase 1/2 trial of ATR-04 to include patients with rashes associated with KRAS and MEK inhibitors, in addition to EGFR inhibitor-associated rash. The company said further protocol modifications are expected to facilitate recruitment and accelerate enrollment.

Company

About Azitra, Inc.

Azitra Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology. The company develops topical live biotherapeutic products and engineered protein-based therapeutics designed to address skin diseases by working with the skin microbiome. Its platform combines synthetic biology, microbial engineering, and protein design to create treatments for dermatologic conditions, including rare and hard-to-treat disorders. Azitra Inc. also uses a proprietary microbial library and data-driven screening tools to identify bacterial strains with therapeutic potential. The company’s current product portfolio includes investigational candidates aimed at dermatology and skin-barrier disorders, positioning Azitra Inc. within the specialized market for microbiome-based skin treatments and targeted dermatologic therapeutics.

CEO Mr. Francisco D. Salva · 13 employees · United States · https://azitrainc.com